bioRxiv Science⌕ Search

Biology subjects

Munoz-Sagredo, L.

Publications and source records attributed to Munoz-Sagredo, L..

3 recordsLinked to original sources

Loss of CD44 re-educates pancreatic cancer-associated fibroblasts modulating their fibrotic and immunosuppressive functions

Pancreatic tumors are characterized by a prominent stroma that makes up to 90% of the tumor. Due to the significant upregulation of CD44, a family of transmembrane glycoproteins, in pancreatic cancer-associated fibroblasts (CAFs), we investigated its role in myofibroblastic and inflammatory CAF subsets. Conditional deletion of Cd44 in CAFs in Cd44fl/fl;Pdgfr{beta}CreERT2 mice, significantly decreased the tumor volume. In human CAFs CRIPSR/Cas9-edited to delete CD44, the morphology of the fibroblasts changed drastically: CAFs lost their elongated phenotype and adopted a round shape, reflecting their inactivation. This was accompanied by a significant downregulation of activation markers, unresponsiveness to exogenous stimuli and reduced contractile activity. CD44 absence not only downregulated extracellular matrix proteins in CAFs, thus influencing fibrosis, but also changed the immunomodulatory cytokine secretion. Finally, this inactivation of CAFs upon CD44 deletion influenced their immunosuppressive effect on dendritic cells (DCs) and on cytotoxic T cells (CTLs), resulting in decreased expression of immunosuppressive cytokines in DCs and enhanced tumor-cell-killing by CTLs.

cancer biology↗

Reprogramming Immunosuppressive Bone Marrow Derived Cells via CD44 Targeting Impacts Pancreatic Cancer Metastasis

Pancreatic ductal adenocarcinoma (PDAC) is characterized by early dissemination and an aggressive metastatic course. In order to establish in the liver, metastatic cells require a metastatic niche providing pro-survival signals. Here, we demonstrate that bone marrow-derived cells (BMDCs) establish immunosuppressive niches in the liver that promote metastatic colonization in PDAC. Using an immunocompetent orthotopic PDAC mouse model, we show that BMDCs form clusters enriched in myeloid progenitors and display upregulation of migratory, adhesive, and immunoregulatory programs in response to tumor-derived cues. CD44 and its splice variant CD44v6 are found to be highly expressed on these cells. Hematopoietic-specific deletion of Cd44 or Cd44v6 using Cd44/Cd44v6fl/fl;VavCreERT2mice markedly impairs BMDC clustering, reshapes the BMDC transcriptome, disrupting pathways critical for migration, adhesion, and immunosuppression thereby reducing metastatic burden. Mechanistically, CD44 inhibition blocks BMDC migration toward CCL2, CCL5, and CXCL12, and impairs adhesion to VCAM-1 and fibronectin. Functionally, Cd44-deficient BMDCs exhibit reduced expression of immunosuppressive mediators such as Arginase 1, Ido1, and Il10, and fail to suppress T cell proliferation. Our findings position CD44 as a pleiotropic regulator of BMDC-mediated metastatic niche formation and identify it as a promising therapeutic target to disrupt the pro-metastatic microenvironment in PDAC.

cancer biology↗

Breaking the cycle: How targeting CD44v6/MET signaling disrupts colorectal cancer cell plasticity

The concept of cancer stemness is undergoing rapid evolution, facilitated by technological advances allowing the tracking and elimination of stem cells in vivo. Following their identification in solid tumors, cancer stem cells were placed at the center of tumor initiation, growth and metastasis. However, increasing evidence suggests that stemness is a cellular state that can be acquired by differentiated cells in a process called plasticity. Here we show that CD44v6 may act as a molecular switch controlling plasticity of colorectal cancer cells. CD44v6/MET signaling controls the reappearance of Lgr5+ cells after ablation, in vitro and in vivo as demonstrated in tumor organoids derived from Lgr5DTR/eGFP mice using a CD44v6 blocking peptide. CD44v6 also affects the YAP/TAZ signaling pathway, involved in the very first steps of plasticity. In view of the essential role of plasticity for the establishment of metastases, blocking CD44v6 signaling may represent a pivotal and promising therapy. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=94 SRC="FIGDIR/small/614761v1_ufig1.gif" ALT="Figure 1"> View larger version (17K): org.highwire.dtl.DTLVardef@180b990org.highwire.dtl.DTLVardef@16c19corg.highwire.dtl.DTLVardef@113e5org.highwire.dtl.DTLVardef@c130d3_HPS_FORMAT_FIGEXP M_FIG C_FIG

cancer biology↗